| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Domingo Pascual-Figal | Q73812518 |
| P2093 | author name string | Rudolf A de Boer | |
| Wouter C Meijers | |||
| A Rogier van der Velde | |||
| P433 | issue | Pt A | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 115-121 | |
| P577 | publication date | 2015-06-19 | |
| P1433 | published in | European Journal of Pharmacology | Q1376712 |
| P1476 | title | Galectin-3 and post-myocardial infarction cardiac remodeling | |
| P478 | volume | 763 |
| Q90069019 | Association between Galectin-3 levels within central and peripheral venous blood, and adverse left ventricular remodelling after first acute myocardial infarction |
| Q64964716 | Berberine inhibits cardiac remodeling of heart failure after myocardial infarction by reducing myocardial cell apoptosis in rats. |
| Q92309063 | Cardiac Chagas Disease: MMPs, TIMPs, Galectins, and TGF-β as Tissue Remodelling Players |
| Q64328935 | Cystatin C and galectin-3 as therapeutic targets in heart failure |
| Q50526943 | Early Anti-inflammatory and Pro-angiogenic Myocardial Effects of Intravenous Serelaxin Infusion for 72 H in an Experimental Rat Model of Acute Myocardial Infarction. |
| Q39434474 | From Inflammation to Fibrosis-Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities |
| Q59805634 | Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities |
| Q49830769 | Galectin-3 and outcomes after anterior-wall myocardial infarction treated by primary percutaneous coronary intervention. |
| Q40057919 | Galectin-3 and risk of ischemic stroke in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort. |
| Q47329197 | Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). |
| Q41716070 | Galectin-3, a marker of cardiac remodeling, is inversely related to serum levels of marine omega-3 fatty acids. A cross-sectional study. |
| Q47733264 | Galectin-3: an emerging biomarker in stroke and cerebrovascular diseases |
| Q59189096 | Left ventricular remodeling after the first myocardial infarction in association with LGALS-3 neighbouring variants rs2274273 and rs17128183 and its relative mRNA expression: a prospective study |
| Q91594685 | Myocardial Injury After Ischemia/Reperfusion Is Attenuated By Pharmacological Galectin-3 Inhibition |
| Q64061682 | Perindopril and a Galectin-3 Inhibitor Improve Ischemic Heart Failure in Rabbits by Reducing Gal-3 Expression and Myocardial Fibrosis |
| Q54110304 | Pharmacological inhibition of the mitochondrial NADPH oxidase 4/PKCα/Gal-3 pathway reduces left ventricular fibrosis following myocardial infarction. |
| Q40085529 | Predictive Value for Galectin 3 and Cardiotrophin 1 in Hemodialysis Patients |
| Q26738521 | Prognostic biomarkers in acute coronary syndrome |
| Q38816590 | ST2 and Galectin-3: Ready for Prime Time? |
| Q40908249 | Soluble galectin-3 is associated with premature myocardial infarction. |
| Q38729745 | TAM receptor tyrosine kinase function and the immunopathology of liver disease |
Search more.